Sarah Sammons: Demographics of patients with hepatoxicity from ribociclib
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared on X:
“Nice data from ESMO 2024 poster on demographics of patients with hepatoxicity from ribociclib.
Patients with hepatoxicity were twice as likely to have baseline LFT elevations (mild hepatic impairment) and median BMI was high in hepatic impairment group.”
Source: Sarah Sammons/X
Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer. Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023